In this article, we discuss the 15 best fast growth stocks to buy right now.
In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market expectations of 2.7% and a deceleration from the 3.1% growth observed in the third quarter. This slowdown was primarily driven by declines in business investment and exports, partially offset by increased consumer and government spending. For the entire year, the economy grew by 2.8%, marginally less than the 2.9% growth recorded in 2023. Inflationary pressures persisted, with the price index for gross domestic purchases rising by 2.2% in the fourth quarter, up from 1.9% in the previous quarter.
Investor sentiment has been influenced by policy uncertainties stemming from the Trump administration’s rapid and sometimes unpredictable policy shifts. Actions on tariffs, immigration, and federal budget cuts have introduced volatility into the market, leading to concerns about potential inflationary pressures and slowed economic growth. David Kelly, Chief Global Strategist at JP Morgan Asset Management, highlighted that such uncertainties could dampen business investment and consumer confidence. This sentiment is reflected in recent Federal Reserve reports indicating a reduction in capital spending and a decline in small business investment expectations.
Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs.
The combination of sluggish growth and persistent inflation has reignited fears of stagflation—a scenario characterized by stagnant economic growth coupled with high inflation. Trade policies, including tariffs on Chinese imports and plans for additional tariffs on various goods, have contributed to these concerns. While inflation remains below the peaks of the 1970s, ongoing trade tensions have raised the prospect of growth-impeding inflationary pressures. Investors are cautiously optimistic about stocks but are increasingly wary of potential stagflation risks.
Despite these challenges, growth stocks have demonstrated resilience. The S&P 500 index experienced its best week since late January, breaking a two-week losing streak. Analysts Jeff Blazek and Erik Knutzen of Neuberger Berman noted a shift in investor focus from inflation concerns to growth prospects, suggesting that expectations of economic expansion are now exerting a more significant influence on the market. This shift has been accompanied by strong performances in US value stocks, industrials, financials, and European equities.
Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities.
To come up with the 15 best fast growth stocks to buy right now, we went over multiple rankings on the internet to compile an initial list of fast growth stocks. We then examined the hedge fund sentiment of each stock and picked the most popular ones. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A portfolio manager studying various stocks and other securities on a tablet.
Best Fast Growth Stocks To Buy Right Now
15. Lantheus Holdings, Inc. (NASDAQ:LNTH)
Number of Hedge Fund Holders: 39
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a radiopharmaceutical company that specializes in the development and distribution of precision diagnostic and therapeutic products. As of the third quarter of 2024, worldwide revenue was $378.7 million, showing an increase of 18.4% from the third quarter of the prior year. In January, the company signed a definitive agreement to acquire Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, in an all-cash deal. The agreement includes an upfront payment of $250 million, with the potential for an additional $752.5 million in milestone payments. The acquisition expands Lantheus’ oncology diagnostic pipeline by adding OCTEVY, a PET diagnostic agent for neuroendocrine tumors (NETs), and several novel theranostic pairs in clinical and pre-clinical stages.
